Risk stratification model based on estimated dose of radiation to immune cells and radiotherapy-related nadir lymphocyte count for predicting the efficacy of consolidation immunotherapy in stage III non-small cell lung cancer

09 Jul 20266 min read0 viewsJournal Feed

GIST (Key Takeaways)

PurposeThis study aimed to evaluate the prognostic value of the estimated dose of radiation to immune cells (EDRIC) and the radiotherapy-related nadir lymphocyte count (RT-NLC), and to establish a risk stratification model for predicting outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiotherapy (CRT) and immunotherapy. Materials and methodsWe retrospectively analyzed 136 patients treated between May 2019 and November 2023. EDRIC and RT-NLC were dichotomized at median values.
Survival analysis was performed using Kaplan–Meier and Cox regression. High-risk patients were defined as having EDRIC ≥ 6.75 Gy and RT-NLC < 0.54×109/L.Results. EDRIC inversely correlated with RT-NLC (r = –0.38, P < 0.001).
Lower EDRIC was associated with significantly improved median overall survival (OS: 49.7 vs. 38.1 months, P = 0.015), progression-free survival (PFS: 29.7 vs. 17.3 months, P = 0.006), locoregional relapse-free survival (LRFS: 32.4 vs.
19.8 months, P = 0.004), and distant metastasis-free survival (DMFS: 44.8 vs. 24.0 months, P = 0.001).

Clinical Editorial

Frontiers in Immunology published a clinical update in Infectious Disease on 09 Jul 2026.

The item focuses on Risk stratification model based on estimated dose of radiation to immune cells and radiotherapy-related nadir lymphocyte count for predicting the efficacy of consolidation immunotherapy in stage III non-small cell lung cancer.

Review the original article for the full source wording and details.